tradepost.ai Logo
Newsletter InsightsSEC AnalysisAI Top20 IndexPricing
Log in
Start free trial
tradepost.ai Logo

Empowering Traders with AI

Quick Links

Newsletter InsightsSEC AnalysisPricingFAQ

Legal

Privacy PolicyCookies PolicySecurity Disclosure PolicyTerms & ConditionsDisclaimer

Copyright © 2025 Dutchcode B.V. All rights reserved.

10-Q - INNOVATIVE MEDTECH, INC. (0001331612) (Filer)

Tue, May 20, 7:33 PM (32 days ago)

**Innovative MedTech, Inc. (IMTH) Q1 2025 Financial Summary** **Financial Health:** - **Revenue:** $0 for Q1 2025, due to reclassification from discontinued operations. - **Net Loss:** $117,510 for Q1 2025, a decrease from $865,105 in Q1 2024. - **Operating Expenses:** $56,659 for Q1 2025, down from $865,194 in Q1 2024. - **Cash Flow:** $351,000 in cash available for operations as of March 31, 2025, insufficient for next 12 months. - **Liabilities:** $5,955,434 in total liabilities, including long-term debt. - **Stockholders' Deficit:** $4,892,218 as of March 31, 2025. **Performance Metrics:** - **Gross Margin:** Not applicable due to zero revenue. - **Profit Margins:** Negative due to operating losses. - **Earnings Changes:** Net loss decreased by $747,595 in Q1 2025 compared to Q1 2024. **Quarterly Performance:** - **Operating Expenses:** Decreased by 93.45% in Q1 2025 due to reduced consulting, stock-based compensation, and general administrative expenses. - **Other (Expense) Income:** Decreased by 68,472% due to increased amortization of debt discount, loss on change in fair value of derivatives, and interest expenses. **Trends & Uncertainties:** - **Going Concern:** Substantial doubt about the company's ability to continue as a going concern due to limited liquidity and reliance on additional financing. - **Legal Proceedings:** Ongoing litigation and defaulted notes may impact future operations. - **Future Operations:** Plans to raise capital through equity offerings and debt obligations to fund operations and develop new products. **Discontinued Operations:** - **Revenue:** $431,017 for Q1 2025, down from $455,164 in Q1 2024. - **Operating Expenses:** Decreased by 20.25% in Q1 2025. - **Gain (Loss):** Improved by 164.24% in Q1 2025 due to increased operating expenses. **Future Outlook:** - **Capital Raising:** Plans to seek additional financing to secure funding for operations. - **New Products:** Focus on developing new products and expanding into advanced wound care treatment. - **Strategic Shifts:** Potential acquisitions and partnerships to drive growth.